X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4, that is being developed as an oral, once-daily therapy. It has developed a pipeline of small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). We show 25 historical shares outstanding datapoints in our XFOR shares outstanding history coverage, used to compute XFOR market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing XFOR market cap history over the course of time is important for investors
interested in comparing XFOR's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of XFOR versus a peer is one thing; comparing
XFOR market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like XFOR can fluctuate over the course of history.
With this page we aim to empower investors researching XFOR by allowing them to research the XFOR market cap history. |
Free XFOR Email Alerts:
Video: The Importance of Market Cap
